What the FDA's July 2026 Peptide Hearing Actually Decided

On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) met at the agency’s White Oak campus in Silver Spring, Maryland, to consider whether seven peptides should be added to the Section 503A Bulk Drug Substances List (FDA meeting notice). The committee recommended six — BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax — and voted against emideltide, also known as delta sleep-inducing peptide (DSIP) (Mintz, July 29, 2026). The votes The recommendations went against FDA’s own scientific staff, who had assessed each peptide and recommended against including all seven, citing a lack of clinical data and insufficient characterization (Mintz). Day one (July 23): BPC-157, evaluated for ulcerative colitis, and KPV, evaluated for wound treatment and inflammatory conditions, each passed 8–6 with one abstention. TB-500 and MOTS-c also received favorable votes (Regulatory Focus / RAPS, July 23, 2026; RAPS, July 24, 2026). Day two (July 24): Epitalon was recommended for insomnia, 7–5 with one abstention. Semax was recommended for cerebral ischemia, migraine, and trigeminal neuralgia, 8–5. Emideltide — proposed for insomnia, narcotic dependence, and opioid withdrawal — was rejected 6–7 with one abstention (RAPS, July 24, 2026). What was said FDA reviewer Russell Wesdyk asked during the BPC-157 session, “What is BPC-157?”, adding that the agency cannot establish quality standards until more is known about the substance (RAPS, July 23, 2026). On emideltide, FDA’s Katie Park cited “a lack of safety and efficacy data” for the proposed uses (RAPS, July 24, 2026). Of the 24 speakers who commented on BPC-157, four were scientists opposing wider access; the other 20 were doctors, chemists, and peptide business owners in favor (CBS News). NYU Langone endocrinologist Dr. Rachel Pessah-Pollack, noting BPC-157 has been tested in roughly 30 humans, said “Anecdotes are not evidence” (CBS News). Longevity influencer Gary Brecka testified in support: “This is not a question of whether Americans will use peptides” (TIME). Rita Jew, pharmacist and president of the Institute for Safe Medication Practices, said ahead of the meeting, “This is really alarming” (Associated Press). What has not changed Nothing is legally different today. An advisory committee vote is not agency action, and FDA must still decide whether to accept the recommendations through notice-and-comment rulemaking (Mintz). None of the six is eligible for 503A compounding as of this writing. A second PCAC meeting covering five additional peptides is expected in February 2027 (Mintz). Mintz also notes that even if FDA adds these substances to the list, federal and state advertising law generally requires competent and reliable scientific evidence behind health claims — meaning terms like “clinically proven” would remain off-limits for these compounds (Mintz). Reference: the seven compounds reviewed BPC-157 — A synthetic peptide derived from a sequence found in human gastric juice. Assessed by FDA for ulcerative colitis (Mintz). FDA staff stated there is a lack of evidence supporting effectiveness for that use, and that the substance is not well characterized. Briefing materials described three adverse event reports following BPC-157 injection, while noting it is unclear whether the events were attributable to BPC-157 (RAPS). Published research is overwhelmingly preclinical; see Sikiric et al., Biomedicines 2022, doi:10.3390/biomedicines10112696, a review of animal-model cardiovascular findings. Human testing is limited to approximately 30 people (CBS News). KPV — Reviewed for wound treatment and inflammatory conditions (RAPS). Recommended 8–6 with one abstention. TB-500 — Reviewed on day one and recommended by the committee (RAPS). Along with BPC-157, it was placed in 2023 on a list of substances considered too high-risk for pharmacy compounding (Associated Press). MOTS-c — Reviewed on day one and recommended by the committee (RAPS). Epitalon — Proposed for insomnia; recommended 7–5 with one abstention. FDA stated there are no publications discussing efficacy of epitalon in patients with insomnia, and cited immunogenicity risk potentially amplified by aggregation. Committee member Tod Durham cited poor characterization and potential carcinogenicity risk in voting no; William Zamboni of UNC cited a significant lack of safety data (RAPS). Semax — Proposed for cerebral ischemia, migraine, and trigeminal neuralgia; recommended 8–5 (RAPS). Emideltide (DSIP) — Proposed for insomnia, narcotic dependence, and opioid withdrawal; rejected 6–7 with one abstention. FDA’s briefing package said the peptide is not adequately characterized and carries potential for peptide-related impurities from incomplete coupling reactions, truncations, or side reactions, and noted approved therapies already exist for those conditions. John Hertig of the Collaborative for Evidence-Based Medicines testified that the most recent study on the substance was 30 years old (RAPS). All products listed on Grey Wolf Research are sold for research use only and are not for human consumption. This article reports on a regulatory proceeding and is not medical advice.